Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2008
03/12/2008CN100374158C application of agent for lowering the cell ATP level in preparing medicine
03/12/2008CN100374116C Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
03/12/2008CN100374114C Antibiotic compositions for treatment of the eye, ear and nose
03/12/2008CN100374110C Local preparation containing poloxamer and other microbe killing agent and applicator
03/12/2008CN100374044C Primary composition containing lipophilic bioactive compound
03/11/2008US7342043 Medicinal compositions improving brain function and method for improving brain function
03/11/2008US7342034 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
03/11/2008US7342028 Medical use for tachykinin antagonists
03/11/2008US7342017 Vanilloid Receptor 1 and metabotropic glutamate receptor 1 inhibitors; inhibition of capsaicin-induced or PH-induced activation of vanilloid receptors; antidepressant; anxiolytic agent; analgesics; addictive disorders; antiemetic agent
03/11/2008US7342016 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives; use in combination with antineoplastic agents such as cisplatin
03/11/2008US7341995 Use of SARP-1 for the treatment and/or prevention of scleroderma
03/11/2008US7341842 TRP8, a transient receptor potential channel expressed in taste receptor cells
03/11/2008US7341739 Small particle liposome aerosols for delivery of anti-cancer drugs
03/11/2008US7341733 Pertussis toxin and analogs exhibit an adenosine-5* diphosphate-ribosyltransferase activity, useful in promoting prophylactic and/or therapeutic responses against another target antigen in a mammal patient
03/11/2008US7341728 Internalisation of virus into cells
03/11/2008CA2444561C Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
03/11/2008CA2195425C Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
03/06/2008WO2008027854A2 Pharmaceutical compositions comprising hgh for oral delivery
03/06/2008WO2008027839A1 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
03/06/2008WO2008027532A2 Pharmaceutical compositions including vitamin d and corticosteroid
03/06/2008WO2008027445A2 Combination with bis(thiohydrazide amides) for treating cancer
03/06/2008WO2008027013A2 Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
03/06/2008WO2008026781A1 Reverse targeting lipid vesicle
03/06/2008WO2008026776A1 Transdermal composition, transdermal pharmaceutical composition and transdermal cosmetic composition comprising polymer micelle encapsulating active ingredient
03/06/2008WO2008026769A1 Novel aminopyridine derivative having aurora a-selective inhibitory activity
03/06/2008WO2008026768A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
03/06/2008WO2008026668A1 Medicinal composition containing insulin resistance improving agent
03/06/2008WO2008026298A1 Remedy for kidney disease
03/06/2008WO2008026156A2 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
03/06/2008WO2008026125A2 Anti cancer use of caffeic acid and derivatives
03/06/2008WO2008026012A1 Novel compositions and methods
03/06/2008WO2008025926A2 Salivary substitute
03/06/2008WO2008025543A1 Pharmaceutical compositions for the treatment of fungal infections
03/06/2008WO2008008549A3 Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat neoplasia
03/06/2008WO2008008513A3 Combination treatments
03/06/2008WO2007139943A3 Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders
03/06/2008WO2007137000A3 Combination cancer chemotherapy
03/06/2008WO2007131736A3 Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
03/06/2008WO2007131154A3 Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
03/06/2008WO2007087154A3 Methods for enhancing therapeutic effects of a neurotoxin
03/06/2008WO2007078874A3 Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
03/06/2008WO2007036920A3 Therapeutic use of polyanhydroglucronic acid
03/06/2008US20080058762 Induction And Maintenance Of Tolerance To Composite Tissue Allografts
03/06/2008US20080058505 Modified parathyroid hormone/peptides for use in prevention and treatment of bone disorders
03/06/2008US20080058433 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
03/06/2008US20080058432 Measuring expression levels in a sample of tumor genes from the group consisting of those encoding mRNA corresponding to SEQ ID Nos: 7-28; analyzing the geneexpression to obtain gene expression profiles to predetermined cut-off levels indicative of recurrence; medical prognosis
03/06/2008US20080058431 Screening compounds to treat, stabilize, or prevent a higher than desired total body weight or a higher than desired percentage of body fat if the compound increases Shp2 activity by binding of Shp2 on the leptin receptor; Shp2 agonist; dietetics; eating disorders; glandular disorders
03/06/2008US20080058430 Method For Selecting Allosteric Regulators Of Class III G Protein-Coupled Receptors
03/06/2008US20080058411 Methods For Treating Resistant Or Refractory Tumors
03/06/2008US20080058403 Administering photoactive porphyrin, and awaiting localization in ocular tissue; radiating with laser light; macular degeneration; neovascularization
03/06/2008US20080058363 Pharmaceutical composition for treating fecal incontinence and anal itch
03/06/2008US20080058360 Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseases
03/06/2008US20080058359 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent
03/06/2008US20080058356 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists
03/06/2008US20080058354 Treating erectile dysfunction and female sexual dysfunction; side effect reduction; 1-ethyl-3-(2-hydroxyethyl)-7-(3-bromo-4-methoxyphenyl)-8-(2-hydroxycyclopenylamino)-1,2,3,6-tetrahydro-7H-purine-2,6-dione for example
03/06/2008US20080058345 Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
03/06/2008US20080058322 Small molecule inhibitors targeted at Bcl-2
03/06/2008US20080058314 Novel dicarboxylic acid derivatives with pharmaceutical properties
03/06/2008US20080058306 Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
03/06/2008US20080058301 Therapy for prostate cancer; administering androgen receptor
03/06/2008US20080058263 Polypeptides that binds to cellular receptors; animal growth regukators
03/06/2008US20080058258 Growth Factor
03/06/2008US20080058252 Use of C5A receptor antagonist in the treatment of fibrosis
03/06/2008US20080058247 Polynucleotides and Polypeptides Encoding Receptors
03/06/2008US20080057537 Nucleic acid encoding polypeptide involved in cellular entrance of the PRRS virus
03/06/2008US20080057515 Beta-like glycoprotein hormone polypeptide and heterodimer
03/06/2008US20080057509 Defects in Periaxin Associated with Myelinopathies
03/06/2008US20080057136 An ionogenic surfactant, a metal chelating complex with an affinity for protons, solvent and carrier; preferably cetylpyridinium chloride, EDTA-zinc complex, and isopropanol; fungicides for oral, topical or intravenous administration; dandruff, acne, dermatitis
03/06/2008US20080057131 Glycolic acid-lactic acid copolymer matrix incorporated with a peptide drug and a corticosteroid; sustained release for two weeks; improved bioavailability
03/06/2008US20080057094 Modifying a mineral supplement or animal feed through the addition of effective amounts of garlic and sulfur as insect repellents
03/06/2008US20080057083 Protecting an animal against a pathogen by administering protective agent which is able to stimulate the animal's immune system to produce a response which is protective against the pathogen, and an immunostimulant comprising a polycationic carbohydrate or derivative thereof; non-parenteral immunization
03/06/2008US20080057078 Chicken Anemia Virus Vaccine from Cell Line
03/06/2008US20080057073 Methods of identifying susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling; using reovirus for treatment of cellular proliferative disorders, particularly wherein proliferating cells exhibit constitutive MAPK phosphorylation in mammals; antitumor agents
03/06/2008US20080057069 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue
03/06/2008US20080057045 oral administration of Lactobacillus to ruminants, to prevent growth of escherichia; probiotics
03/06/2008US20080057040 Cell Preservation Method
03/06/2008US20080057034 enterobacter having a mutation in the fnr (fumarate nitrate reductase) gene and comprising a heterologous nucleotide sequence that codes a foreign antigen, used to induce an immune response against a heterologous antigen; vaccines
03/06/2008US20080057032 Combination therapy (temozolomide and alpha-ifn) for advanced cancer
03/06/2008US20080057003 Powder inhaler formulations
03/06/2008CA2670425A1 Pharmaceutical compositions including vitamin d and corticosteroid
03/06/2008CA2662126A1 Anti cancer use of caffeic acid and its derivatives
03/06/2008CA2662086A1 Active pharmaceutical ingredients (apis) with specific water surface areas, pharmaceutical compositions comprising said apis and processes for preparing such compositions and apis
03/06/2008CA2661833A1 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
03/06/2008CA2661694A1 Salivary substitute
03/06/2008CA2660939A1 Pharmaceutical compositions for the treatment of fungal infections
03/06/2008CA2660804A1 Reverse targeting lipid vesicle
03/06/2008CA2659770A1 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
03/06/2008CA2657469A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
03/05/2008EP1894997A1 Improvement of cardiac function by mesenchymal stem cell transplantation
03/05/2008EP1894576A1 Novel triglyceride reducing agent
03/05/2008EP1894575A1 Therapeutic agent for cancer
03/05/2008EP1894567A1 Concomitant pharmaceutical agents and use thereof
03/05/2008EP1893580A1 NOVEL SALT FORM OF A ß2 -ADRENERGIC AGONIST QUINOLIN-2-ONE DERIVATIVE
03/05/2008EP1893291A1 Treatment of sexual dysfunction
03/05/2008EP1893236A2 Direct compression formulation of dpp-iv inhibitors and glitazones, and process
03/05/2008EP1893235A2 Methods for treating dermatitis using mutant human il-4 compositions
03/05/2008EP1893203A2 Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
03/05/2008EP1893186A2 Improved treatment for anemia using a hif-alpha stabilising agent
03/05/2008EP1830883A4 Methods for inhibiting a decline in learning and/or memory in animals
03/05/2008EP1758600A4 Methods and compositions for treating mood disorder
1 ... 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 ... 1151